maja oresnik headshot (002).jpg

Maja Orešnik

Science and research director, PharmaLinea Ltd.

Maja Orešnik is the science and research director at PharmaLinea Ltd.

Latest from Maja Orešnik

thumbnail
Formulation
Navigating 'biotics': Challenges and trends in probiotic and prebiotic formulationsBiotics challenges: Formulating probiotics and prebiotics solutions
byMaja Orešnik
Jan 23, 2024
9 Min Read
Formulating supplements that sway urologists.jpg
Supplements
Formulating supplements that sway urologistsFormulating supplements that sway urologists
byMaja Orešnik
Mar 5, 2021
4 Min Read

All from Maja Orešnik

Formulating strategies to address the booming stress category.jpg
Supplements
Formulating strategies to address the booming stress category
Formulating strategies to address the booming stress category
Dec 16, 2020
|
7 Min Read
byMaja Orešnik
Liver health supplement opportunities.jpg
Healthy Living
Liver health supplement market not meeting consumer demand
Liver health supplement market not meeting consumer demand
Sep 26, 2019
|
4 Min Read
byMaja Orešnik
Eye health supplement market opportunities.jpg
Healthy Aging
Research lacking in the eye health supplement market
Research lacking in the eye health supplement market
Sep 17, 2019
|
9 Min Read
byMaja Orešnik
Nutraceuticals for immune support.jpg
Immune Health
Nutraceuticals for immune support: Growing standards, room for improvement
Nutraceuticals for immune support: Growing standards, room for improvement
Jun 24, 2019
|
5 Min Read
byMaja Orešnik

Recommended

Supplement Regulations
NY law targeting dietary supplements mired in CRN, NPA litigation
NY law targeting dietary supplements mired in CRN, NPA litigation

Mar 13, 2024

Supplement Regulations
FDA seeks dietary supplement listing requirement in FY25 budget proposal
FDA seeks dietary supplement listing requirement in FY25 budget proposal

Mar 12, 2024

Supplement Regulations
FDA NDI guidance: Five key takeaways
FDA NDI guidance for supplement companies: Five key takeaways

Mar 12, 2024

Market Trends & Analysis
Amway’s revenues continue decade-long slide, dropping to $7.7 billion
Amway's annual revenues drop by 5%

Mar 12, 2024

Recent headlines
Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.